Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca's global biologics R&D arm MedImmune has entered into a new five-year, multi-project collaboration with the University of Cambridge's Department of Chemical Engineering and Biotechnology (CEB) to focus on generating breakthrough research in biopharmaceutical development (BPD).
Subscribe to our email newsletter
BPD is a field that includes cell engineering, continuous processing, formulation and analytical science, to support development of potential new therapies.
The research collaboration will see MedImmune and CEB use a new partnership model to discover and develop multiple strategic research projects, drawing on resources and expertise from both organizations.
Scientists and academics from both the parties will work alongside each other to advance bioprocessing research as well as provide a range of educational opportunities to cultivate and support BPD scientists.
MedImmune Biopharmaceutical Development senior vice-president Dr Gail Wasserman said: "Working with leading academics at a world-class University gives us a unique ability to shape the drug development processes of the future.
"It is a great example of how to engage the best scientific expertise available and to support the development of talented scientists.
"This partnership will have a significant impact on MedImmune’s capacity to advance research in critical treatment areas, acting as a beacon of BPD research excellence with the critical mass to attract further research and to provide educational opportunities for the next generation of scientists."
The research collaboration will also seek additional grant funding and other opportunities where appropriate to help create further critical mass in high quality BPD research.